Pembrolizumab Elicits Responses in Classical Hodgkin Lymphoma

December 6, 2014 11:18 PM

13 0

Of the 29 evaluable patients with cHL who received pembrolizumab, six patients (21%) experienced complete remission while 13 patients (45%) achieved a partial remission, Moskowitz said during a press briefing as the meeting opened Saturday. Among the remaining participants, six patients (21%) had stable disease while four individuals (14%) experienced progressive disease.

The patients who participated in the trial had been heavily pretreated, having received a median of four prior therapies. In total, 69% of the patients (n = 20) had relapsed following stem cell transplant and, by trial design, all patients had failed treatment with brentuximab vedotin. Patients rang...

Read more

To category page